Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 24, 2021Journal of Clinical OncologyOpen Access

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

View Full Paper
Ask AI
Bookmark
Share

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

A 2021 study studied this question.

synapsesocial.com/papers/6a7cfae7448628eb7e2fa802https://doi.org/10.1200/jco.21.02229
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma2019 · 3,804 citations
  2. 2Challenges of Guarantee-Time Bias2013 · 463 citations
  3. 3Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects2011 · 584 citations
  4. 4Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma2015 · 2,811 citations
  5. 5Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC2017 · 574 citations